LCM
MCRB icon

Landscape Capital Management’s Seres Therapeutics MCRB Stock Holding History

Landscape Capital Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-631
Closed -$70.6K – 730
2022
Q4 		$70.6K Hold
631
– – 0.01% 771
2022
Q3 		$81K Buy
+631
New +$64.6K 0.01% 908
2015
Q3 		– Sell
-2,325
Closed -$1.93M – 702
2015
Q2 		$1.93M Buy
+2,325
New +$2.03M 0.33% 65

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Landscape Capital Management's MCRB Position: Q1 2023 in Review

Landscape Capital Management sold out of Seres Therapeutics (MCRB) in Q1 2023, closing a stake of 631 shares — an estimated $70.6K sold.

Landscape Capital Management first reported a position in MCRB in Q2 2015 and held it in 3 quarters. The position peaked at $1.93M in Q2 2015. 123 funds tracked by Wall St. Rank hold MCRB as of Q1 2023.

  • Landscape Capital Management reported no remaining Seres Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Landscape Capital Management sold 631 Seres Therapeutics shares in Q1 2023, an estimated $70.6K.
  • Landscape Capital Management first reported a position in Seres Therapeutics in Q2 2015 and held it in 3 quarters.
  • Landscape Capital Management's Seres Therapeutics position peaked at $1.93M in Q2 2015.
  • 123 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2023.

Based on Landscape Capital Management's 13F filing for Q1 2023, filed 10 May 2023.